SCHEMBL23611575

SCHEMBL23611575

COC1CCC2c3ccccc3C1N2C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
FFAR2 O15552 16/20 0.39
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23611614 0.82 CHRM2 (0.40) FFAR2
SCHEMBL23611571 0.80 CYP3A4 (0.46) FFAR2
SCHEMBL23611591 0.80 CYP3A4 (0.46) FFAR2
SCHEMBL23611546 0.80 CYP3A4 (0.46) FFAR2
SCHEMBL23611631 0.79 FFAR2 (0.43) FFAR2
SCHEMBL23611599 0.78 FFAR2 (0.37) FFAR2
SCHEMBL23611542 0.77 FFAR2 (0.36) FFAR2
Hydrochloric Acid SCHEMBL23611565 0.72 OPRM1 (0.31)
SCHEMBL21637895 0.70 NOTUM (0.44) FFAR2
SCHEMBL13116616 0.67 FFAR2 (0.39) FFAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230116114-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS BLUE OAK PHARMACEUTICALS, INC. 2023-04-13 US disclosed
WO-2021138314-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS BLUE OAK PHARMACEUTICALS, INC. (US) 2021-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230116114-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS PMP22, CHAT, ACHE FFAR2 2338/4885MEN1 933/4885KMT2A 1869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.